References
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244–279.
- Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 2009 Nov;84(11):979–984.
- De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French survey. Arth Res Ther. 2005;7(3):R545–R551.
- Kang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21(5):946–949.
- Cairns AP, Duncan MK, Hinder AE, et al. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61(11):1031–1032.
- Hart SP, Dougherty GJ, Haslett C, et al. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol. 1997;159(2):919–925.
- Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64(3):403–407.
- Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5(6):694–697.
- Lorenz HM, Herrmann M, Winkler T, et al. Role of apoptosis in autoimmunity. Apoptosis. 2000;5(5):443–449.
- Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48(7):716–720.
- Gonnet-Gracia C, Barnetche T, Richez C, et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol. 2008;26(3):401–407.
- Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20(2):147–161.
- Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5(4):285–294.
- Maczynska I, Millo B, Ratajczak-Stefanska V, et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNFalpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol Lett. 2006;102(1):79–82.
- Costa MF, Said NR, Zimmermann B. Drug induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008 Jun;37(6):381–387.
- Liggi M, Gilli A, Lai MA, et al. A lupus-like syndrome induced by infliximab treatment. Clin Res Hepatol Gastroenterol. 2011 Oct;35(10):685–687.
- Katz U, Zandmand-Goddard G. Drug induced lupus. Autoimmun Rev. 2010;10:46.
- Kocharla L, Mongey AB. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus. 2009 Feb;18(2):169–171.
- Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann NY Acad Sci. 2007 Jun;1108:166–182.
- Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43(11):2383–2390.
- Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine(Baltimore). 2007 Jul;86(4):242–251.